预约演示

Theratechnologies to phase out preclinical oncology program as it looks for R&D partner

2024-03-25

临床1期多肽偶联药物

While it's not clear how many jobs will be lost in the phase out, the move will reportedly cost the company about $625,000 in cash for severance payouts.

Theratechnologies is winding down its preclinical oncology research program in an effort to turn a profit and focus on its commercial business. The biotech will use what it has learned from the cancer work conducted so far to find an outside R&D collaborator.

Theratechnologiesestment in a platform to treat multiple types of cancer by targeting the SORT1+ receptor “has generated important evidence on multiple peptide-drug conjugates with different paycancer” CEO Paul Lévesque said in a March 22 release. “Now that we have significantly advanced our preclinical program, we are well-positioned to leverage this wealth of data and insights to attract an oncology R&D partner.”

The move will cost the company about $625,000 in severance payoutscancerther expenses as wSORT1s $770,000 in non-cash charges. Six jobs will be cut as a result of the changes, but given that they'll happen over the coming months, no one will be impacted immediately, a spokesperson for Theratechnologies told Fierce Biotech.

The decision does not affect clinical progress for Theratechnologies’ lead oncology asset, a peptide-drug conjugate called sudocetaxel zendusortide. That therapy is currently being tested in a phase 1 trial for advanced ovarian cancer after overcoming an FDA hold over safety concerns.Theratechnologies

Moving forward, Theratechnologies will continue to Theratechnologiesnerated prior to the preclinical wind down. The company plans to przendusortidesters at the upcoming American Association for Cancer Research aadvanced ovarian cancerApril, including one FDAh data on new peptide-drug conjugates.

TheratechnologieTheratechnologiesroved drugs on the market, both for HIV: An antiretroviral called Trogarzo for patients infected with HIV-1; and a growth hormone-releasing factor called EgriftaCancerh reduces the build-up of excess visceral abdominal fat that sometimes results from the condition. The company is also exploring the active ingredient of Egrifta, tesamorelin, as a potential treatment for metabolic dysfunction-associated steatohepatitis.